Molecular dynamics simulations of a central nervous system-penetrant drug AZD3759 with lipid bilayer

Liang, Yan-Shu; Zhi, Shuang; Qiao, Zhixia; Meng, Fancui

doi:10.1007/s00894-022-05266-w

Search citation statements

Order By: Relevance

Paper Sections

Select...

Treatment Of Nsclc-lm1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AZD3759 is a new generation of EGFR-TKI and specially designed to penetrate the BBB. 46 , 47 In preclinical studies, AZD3759 showed excellent penetration of the BBB. 48 The Kpuu, CSF (ratio of free drug concentration in CSF to plasma) and Kpuu, brain (ratio of free drug concentration in brain to plasma) of AZD3759 are approximately 1, indicating that almost all AZD3759 can reach the brain.…”

Section: Treatment Of Nsclc-lmmentioning

confidence: 99%

The Riddle of the Sphinx: Progress in Leptomeningeal Metastasis of Non–Small Cell Lung Cancer

Zhao,

Yu,

Wang

et al. 2023

Clin Med Insights Oncol

View full text Add to dashboard Cite

Leptomeningeal metastasis (LM) is a serious complication of advanced non–small cell lung cancer (NSCLC), and the incidence of LM has been increasing yearly in recent times. There is no consensus on the best treatment modality for LM, which underscores a difficult problem in the management of advanced NSCLC patients. The existing treatments include molecular targeted therapy, systemic chemotherapy, local radiotherapy, antivascular tumor therapy, intrathecal chemotherapy, and immunotherapy, but their efficacy is not satisfactory. In this article, we briefly describe the clinical manifestations, diagnosis, and treatment of NSCLC-LM and discuss progress regarding evaluation of the efficacy of LM treatment to better provide a necessary reference for clinical practice and clinical trial evaluation.

show abstract

Section: Treatment Of Nsclc-lmmentioning

confidence: 99%